Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AL102 for the treatment of progressing desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor.
Ayala Pharmaceuticals Announced Fast Track Designation Granted by US FDA
